Showing 6 posts of 6 posts found.

AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment

November 6, 2023
Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …

CHMP gives positive opinion recommending authorisation to GSK’s CKD drug

June 26, 2023
Medical Communications CKD, EMA, Nephrology

Global biopharmaceutical company GSK has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …


Astellas receives positive CHMP opinion for symptomatic anaemia drug

June 28, 2021
Sales and Marketing Astellas, CKD, anaemia

Astellas and FibroGen have announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted …

Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …


Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

March 30, 2016
Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …

astrazeneca image

AstraZeneca signs $350m kidney deal

August 1, 2013
Sales and Marketing AstraZeneca, CKD, fibrogen, kidney

AstraZeneca has signed a deal with private biotech company FibroGen to develop a novel compound aimed at treating anaemia associated …

Latest content